AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Up 18.7% in April

AngioDynamics, Inc. (NASDAQ:ANGO) was the recipient of a significant growth in short interest in April. As of April 15th, there was short interest totaling 2,161,213 shares, a growth of 18.7% from the March 31st total of 1,821,431 shares. Approximately 5.6% of the company’s stock are sold short. Based on an average daily volume of 661,671 shares, the days-to-cover ratio is presently 3.3 days.

Institutional Investors Weigh In On AngioDynamics

Several large investors have recently modified their holdings of the company. Hsbc Holdings PLC boosted its holdings in shares of AngioDynamics by 9.4% in the first quarter. Hsbc Holdings PLC now owns 68,255 shares of the medical instruments supplier’s stock valued at $773,000 after acquiring an additional 5,888 shares during the period. Y Intercept Hong Kong Ltd boosted its holdings in shares of AngioDynamics by 18.3% in the first quarter. Y Intercept Hong Kong Ltd now owns 80,391 shares of the medical instruments supplier’s stock valued at $914,000 after acquiring an additional 12,436 shares during the period. SG Americas Securities LLC boosted its holdings in shares of AngioDynamics by 24.1% in the first quarter. SG Americas Securities LLC now owns 37,158 shares of the medical instruments supplier’s stock valued at $422,000 after acquiring an additional 7,220 shares during the period. Mercer Global Advisors Inc. ADV boosted its holdings in shares of AngioDynamics by 38.1% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 14,604 shares of the medical instruments supplier’s stock valued at $188,000 after acquiring an additional 4,030 shares during the period. Finally, XTX Topco Ltd boosted its holdings in shares of AngioDynamics by 69.6% in the fourth quarter. XTX Topco Ltd now owns 40,811 shares of the medical instruments supplier’s stock valued at $524,000 after acquiring an additional 16,742 shares during the period. 89.43% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Freedom Capital raised AngioDynamics to a “strong-buy” rating in a report on Monday, April 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a report on Monday, April 20th. Zacks Research downgraded AngioDynamics from a “strong-buy” rating to a “hold” rating in a report on Monday, March 30th. Finally, Canaccord Genuity Group lowered their price target on AngioDynamics from $18.00 to $16.00 and set a “buy” rating for the company in a report on Monday, April 6th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, AngioDynamics presently has a consensus rating of “Moderate Buy” and an average price target of $18.67.

AngioDynamics Stock Up 2.0%

Shares of ANGO opened at $11.16 on Friday. The stock has a 50 day moving average price of $10.81 and a 200 day moving average price of $11.49. The company has a market capitalization of $461.13 million, a price-to-earnings ratio of -14.88 and a beta of 0.37. AngioDynamics has a 52-week low of $8.36 and a 52-week high of $13.99.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Thursday, April 2nd. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04. The business had revenue of $78.42 million during the quarter, compared to the consensus estimate of $76.77 million. AngioDynamics had a negative return on equity of 4.66% and a negative net margin of 10.01%. On average, equities analysts anticipate that AngioDynamics will post -0.19 EPS for the current fiscal year.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.